| Identification | Back Directory | [Name]
ML162 | [CAS]
1035072-16-2 | [Synonyms]
ML162
2-Chloro-N-(3-chloro-4-methoxyphenyl)-N-{2-oxo-2-[(2-phenylethyl)amino]-1-(2-thienyl)ethyl}acetamide | [Molecular Formula]
C23H22Cl2N2O3S | [MOL File]
1035072-16-2.mol | [Molecular Weight]
477.403 |
| Chemical Properties | Back Directory | [Boiling point ]
699.3±55.0 °C(Predicted) | [density ]
1.342±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:10.0(Max Conc. mg/mL);20.95(Max Conc. mM)
DMSO:25.0(Max Conc. mg/mL);52.37(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);2.09(Max Conc. mM) | [form ]
A crystalline solid | [pka]
13.84±0.46(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
ML-162 is an inhibitor of glutathione peroxidase 4 (GPX4) and decreases GPX4 levels in MDA-MB-231 breast cancer cells, as well as the viability of BT-549 breast cancer cells. | [Uses]
ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines[1][2] | [storage]
Store at -20°C | [References]
[1] Michel We?wer, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. DOI:10.1016/j.bmcl.2011.09.047
[2] Daiha Shin, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018 Dec;129:454-462. DOI:10.1016/j.freeradbiomed.2018.10.426 |
|
| Company Name: |
Fuxin Pharmaceutical
|
| Telephone: |
+86-021-021-50872116 |
| Website: |
http://www.fuxinpharm.com |
|